Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force.

Abstract

An international task force of investigators from academia, industry, nonprofit foundations, and regulatory agencies met in Monte Carlo, Monaco, on October 31, 2012, to review lessons learned from the recent bapineuzumab and solanezumab trials, and to incorporate insights gained from these trials into future clinical studies. Although there is broad… (More)
DOI: 10.1016/j.jalz.2013.03.007

Topics

Cite this paper

@article{Vellas2013DesigningDT, title={Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force.}, author={Bruno Vellas and Maria Carrillo and Cristina Zugaiar S. Sampaio and Helene Brashear and Eric R. Siemers and Harald Hampel and Lon S. Schneider and Michael W Weiner and Rachelle Doody and Zaven S. Khachaturian and Jesse M. Cedarbaum and Michael J Grundman and Karl Broich and Ezio Giacobini and Bruno Dubois and Reisa Sperling and G. K. Wilcock and Nick C. Fox and Philip Scheltens and Jacques Touchon and Suzanne B. Hendrix and Sandrine Andrieu and Paul S. Aisen}, journal={Alzheimer's & dementia : the journal of the Alzheimer's Association}, year={2013}, volume={9 4}, pages={438-44} }